Japan approves GSK treatment for severe asthma

(Sharecast News) - GSK said Japan's Ministry of Health had approved its bronchial asthma treatment Exdensur after trial results showed "significant reductions" for patients with severe symptoms of the condition. The drug's usage is limited to severe or refractory patients whose asthma symptoms that cannot be controlled with existing treatments and also chronic rhinosinusitis with nasal polyps (CRSwNP).

A second trial showed "significant improvements in nasal polyp size and nasal obstruction, two key measures of disease severity", GSK added on Tuesday.

Approval in Japan marks the third regulatory approval for the treatment, following marketing authorisation from the US and UK. Also known as Depemokimab, it recently received a positive opinion in the EU and it is currently under regulatory review in other countries, including in China, the company added.

Reporting by Frank Prenesti for Sharecast.com